Detalhe da pesquisa
1.
An intronic GAA repeat expansion in FGF14 causes the autosomal-dominant adult-onset ataxia SCA50/ATX-FGF14.
Am J Hum Genet
; 110(1): 105-119, 2023 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36493768
2.
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Brain
; 146(11): 4633-4644, 2023 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37369086
3.
Disability accrual in primary and secondary progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(9): 707-717, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068931
4.
Prediction of relapse activity when switching to cladribine for multiple sclerosis.
Mult Scler
; 29(1): 119-129, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35894247
5.
Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
Mult Scler
; 28(6): 958-969, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34623947
6.
Confirmed disability progression as a marker of permanent disability in multiple sclerosis.
Eur J Neurol
; 29(8): 2321-2334, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35582938
7.
An intronic GAA repeat expansion in FGF14 causes the autosomal-dominant adult-onset ataxia SCA27B/ATX-FGF14.
Am J Hum Genet
; 110(6): 1018, 2023 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37267898
8.
Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.
Mult Scler
; 27(3): 465-474, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32530363
9.
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 90(4): 458-468, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30636699
10.
Neuroprotective Benefits of Antidepressants in Multiple Sclerosis: Are We Missing the Mark?
J Neuropsychiatry Clin Neurosci
; 31(4): 289-297, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30945589
11.
Epidemiology, symptomatology and treatment of patients with myasthenia gravis in an Australian hospital.
Intern Med J
; 49(12): 1537-1540, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31808263
12.
Cladribine versus fingolimod, natalizumab and interferon ß for multiple sclerosis.
Mult Scler
; 24(12): 1617-1626, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28857680
13.
Quality of Acute Care and Long-Term Quality of Life and Survival: The Australian Stroke Clinical Registry.
Stroke
; 48(4): 1026-1032, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28258253
14.
Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients.
Mult Scler
; 22(11): 1495-1498, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26564996
15.
Letter to the editor: FLOUX-PMS study sample considerations.
Mult Scler
; 25(13): 1819-1820, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31538537
16.
Interferon-beta in multiple sclerosis causing thrombotic microangiopathy.
Intern Med J
; 49(2): 274-276, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30754081
17.
COVID-19 Vaccine Status, Intent, Hesitancy, and Disease-Related Beliefs in People with Multiple Sclerosis.
Vaccines (Basel)
; 11(2)2023 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36851287
18.
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.
JAMA Neurol
; 80(7): 739-748, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37273217
19.
A Case of COVID-19 With Myasthenic Crisis.
Cureus
; 14(5): e24936, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35706757
20.
Assessment and treatment of depression in people with multiple sclerosis: A qualitative analysis of specialist clinicians' experiences.
Mult Scler Relat Disord
; 57: 103362, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35158469